RESUMEN
Haloperidol is a neuroleptic medication that is used to treat a wide range of neuropsychiatric conditions. It has been shown to produce medicinal effects against hyperactivity, agitation and mania, as well as schizophrenia. Long-term usage of haloperidol raises the risk of acquiring a neurological condition like Parkinson's disease. Haloperidol causes drug-induced Parkinsonism (DIP) by blocking central dopamine receptors and causing extrapyramidal symptoms during long-term treatment. Quercetin has been shown to reduce the loss of striatal neurons, which may enhance motor capabilities and protect against agents that cause the production of reactive oxygen species (ROS). As a result, present study intended to evaluate the efficacy of quercetin on haloperidol-related motor abnormalities. To develop behavioral impairments, rats (n=24) randomly divided to control and haloperidol group for four weeks. The animals were split into four groups after four weeks: Control, quercetin, haloperidol and haloperidol + quercetin. Animals were administered haloperidol i.p injections of 5mg/kg and quercetin (100mg/kg) orally for 21 days. The treatment of haloperidol-treated rats with quercetin was successful in reversing the haloperidol alterations. It decreased animal food intake and alleviated anxiogenic behavior. The chronic treatment of quercetin further reduced the movement abnormalities in animal model of drug induced pseudo-Parkinson.
Asunto(s)
Antipsicóticos , Enfermedad de Parkinson , Ratas , Animales , Haloperidol/toxicidad , Quercetina/farmacología , Antipsicóticos/efectos adversos , Enfermedad de Parkinson/tratamiento farmacológico , Suplementos DietéticosRESUMEN
Animal models of haloperidol (HAL)-induced neurotoxicity and orofacial dyskinesia (OD) have long been used to study human tardive dyskinesia (TD). Similar to patients with TD, these models show strong pathophysiological characteristics such as striatal oxidative stress and neural cytoarchitecture alteration. Naringin (NAR), a bioflavonoid commonly found in citrus fruits, has potent antioxidative, anti-inflammatory, antiapoptotic, and neuroprotective properties. The present study evaluated the potential protective effects of NAR against HAL-induced OD in rats and the neuroprotective mechanisms underlying these effects. HAL treatment (1 mg/kg i.p. for 21 successive days) induced OD development, characterized by increased vacuous chewing movement (VCM) and tongue protrusion (TP), which were recorded on the 7th, 14th, and 21st day of drug treatment. NAR (30, 100, and 300 mg/kg) was administered orally 60 min before HAL injection for 21 successive days. On the 21st day, after behavioral testing, the rats were sacrificed, and the nitrosative and oxidative status, antioxidation power, neurotransmitter levels, neuroinflammation, and apoptotic markers in the striatum were measured. HAL induced OD development, with significant increases in the frequency of VCM and TP. NAR treatment (100 and 300 mg/kg) prevented HAL-induced OD significantly. Additionally, NAR treatment reduced the HAL-induced nitric oxide and lipid peroxide production, increased the antioxidation power and neurotransmitter levels in the striatum, and significantly reduced the levels of neuroinflammatory and apoptotic markers. Our results first demonstrate the neuroprotective effects of NAR against HAL-induced OD, suggesting that NAR may help in delaying or treating human TD in clinical settings.
Asunto(s)
Modelos Animales de Enfermedad , Discinesias/tratamiento farmacológico , Flavanonas/uso terapéutico , Haloperidol/toxicidad , Discinesia Tardía/inducido químicamente , Discinesia Tardía/tratamiento farmacológico , Animales , Antipsicóticos/toxicidad , Discinesias/metabolismo , Flavanonas/farmacología , Humanos , Mediadores de Inflamación/antagonistas & inhibidores , Mediadores de Inflamación/metabolismo , Masculino , Ratas , Ratas Wistar , Discinesia Tardía/metabolismoRESUMEN
Haloperidol is a first-generation antipsychotic used in the treatment of psychoses, especially schizophrenia. This drug acts by blocking dopamine D2 receptors, reducing psychotic symptoms. Notwithstanding its benefits, haloperidol also produces undesirable impacts, in particular extrapyramidal effects such as tardive dyskinesia (TD), which limit the use of this and related drugs. TD is characterized by repetitive involuntary movements occurring after chronic exposure therapy with haloperidol. Symptoms most commonly manifest in the orofacial area and include involuntary movements, tongue protrusion, pouting lips, chewing in the absence of any object to chew, and facial grimacing. The most serious aspect of TD is that it may persist for months or years after drug withdrawal and is irreversible in some patients. This unit, aimed at facilitating the study of TD, describes methods to induce TD in rats using haloperidol, as well as procedures for evaluating the animals's TD-related symptoms. © 2019 by John Wiley & Sons, Inc.
Asunto(s)
Antipsicóticos/toxicidad , Modelos Animales de Enfermedad , Haloperidol/toxicidad , Masticación/efectos de los fármacos , Discinesia Tardía/inducido químicamente , Animales , Evaluación Preclínica de Medicamentos/métodos , Masculino , Masticación/fisiología , Ratas , Ratas Wistar , Discinesia Tardía/fisiopatologíaRESUMEN
Identification of renin-angiotensin system in the interplay of hypertension and neurodegeneration has paved the way for the repurposing of antihypertensive drugs against Parkinsonism. Losartan carboxylic acid (LCA), the potent AT1 blocker metabolite of losartan, suffers from poor bioavailability and brain access. Since ascorbate transporters have earlier shown enough flexibility as carriers, we have conjugated losartan carboxylic acid to ascorbic acid with the aim of achieving higher oral/brain availability. Ester of LCA and ascorbic acid (FED) was developed keeping in view the substrate specificity of ascorbate transporters. Oral/brain bioavailability was assessed using in vivo pharmacokinetic model. Effect on central nervous system (CNS) and protection against Parkinsonism was evaluated using in vivo models. FED enhanced bioavailability of LCA. The higher brain availability of LCA enabled CNS protection as evident from the increase in locomotor activity, improved motor coordination, and protection against drug-induced catatonia. In conclusion, FED offers an approach to repurpose LCA against Parkinsonism. This can encourage further investigation to simultaneously address hypertension and neurodegeneration.
Asunto(s)
Bloqueadores del Receptor Tipo 1 de Angiotensina II/administración & dosificación , Ácido Ascórbico/administración & dosificación , Losartán/administración & dosificación , Trastornos Parkinsonianos/prevención & control , Sistema Renina-Angiotensina/efectos de los fármacos , Administración Oral , Bloqueadores del Receptor Tipo 1 de Angiotensina II/química , Bloqueadores del Receptor Tipo 1 de Angiotensina II/farmacocinética , Animales , Ácido Ascórbico/química , Conducta Animal/efectos de los fármacos , Disponibilidad Biológica , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Haloperidol/administración & dosificación , Haloperidol/toxicidad , Humanos , Losartán/química , Losartán/farmacocinética , Masculino , Trastornos Parkinsonianos/inducido químicamente , Ratas , Ratas WistarRESUMEN
Adamantane-containing glutamate blocker IEM-1913 (1-amino-4-(1-adamantane-amino)-butane dihydrochloride) equals to memantine in antiparkinsonian potency, but surpasses it in anticonvulsive, antidepressant, and analgesic activities. Moreover, its use is less toxic and safer. IEM-1913 produces significant pharmacological effects at a wide concentration diapason (0.03-1.00 mg/kg), while memantine is effective within a narrow range only (15-20 mg/kg). High pharmacological efficacy and low toxicity of IEM-1913 can be explained by the fact that in contrast to monocationic selective NMDA antagonist memantine, the dicationic glutamate blocker IEM-1913 produces a combined block of cerebral NMDA and AMPA receptors.
Asunto(s)
Hidrocarburos Aromáticos con Puentes/farmacología , Antagonistas de Aminoácidos Excitadores/farmacología , Memantina/farmacología , Putrescina/análogos & derivados , Analgésicos/farmacología , Analgésicos/uso terapéutico , Animales , Anticonvulsivantes/farmacología , Anticonvulsivantes/toxicidad , Antidepresivos/farmacología , Antidepresivos/toxicidad , Antiparkinsonianos/farmacología , Antiparkinsonianos/toxicidad , Hidrocarburos Aromáticos con Puentes/toxicidad , Catalepsia/inducido químicamente , Catalepsia/tratamiento farmacológico , Evaluación Preclínica de Medicamentos , Antagonistas de Aminoácidos Excitadores/toxicidad , Haloperidol/toxicidad , Calor/efectos adversos , Dosificación Letal Mediana , Memantina/toxicidad , Ratones , Pentilenotetrazol/toxicidad , Resistencia Física/efectos de los fármacos , Putrescina/farmacología , Putrescina/toxicidad , Ratas , Ratas Wistar , Receptores AMPA/antagonistas & inhibidores , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Reflejo/efectos de los fármacos , Convulsiones/inducido químicamente , Convulsiones/tratamiento farmacológicoRESUMEN
Tea is the most popular beverage worldwide. Caffeine, the psychoactive principle of tea, pharmacologically interacts with several drugs and bioactive molecules. Epigallocatechin gallate (EGCG) is a major component of tea and its known interactions with caffeine make it worthwhile to further study them by investigating the influence of EGCG on the anticataleptic and locomotor-sensitizing effects of caffeine. In the present investigation, we observed that (a) administration of caffeine or EGCG alone inhibited haloperidol-induced catalepsy, a widely used animal model to study parkinsonism, and (b) a combination of caffeine and EGCG produced greater inhibition of haloperidol-induced catalepsy. Furthermore, after repeated administration of caffeine and EGCG, either alone or in combination, we observed that (c) caffeine and EGCG contrasted the sensitization of catalepsy observed after repeated haloperidol administration by significantly reducing the duration of catalepsy. Furthermore, as haloperidol-induced catalepsy was also associated with increased lipid peroxidation, we observed that (d) EGCG administration reduced striatal lipid peroxide levels in a dose-dependent manner and that (e) the combination of caffeine with EGCG was most effective in reducing haloperidol-increased striatal lipid peroxide. Finally, we observed that (f) chronic caffeine and EGCG significantly elicited locomotor sensitization and that (g) their combination resulted in significantly greater effects. In conclusion, EGCG potentiated the effects of caffeine on haloperidol-induced catalepsy and of caffeine-elicited locomotor sensitization. Overall, these observations indicate critical interactions between caffeine and EGCG in an animal model of parkinsonism and locomotor activity and suggest that tea consumption might reduce antipsychotic-induced side effects.
Asunto(s)
Cafeína/farmacología , Catalepsia/tratamiento farmacológico , Catequina/análogos & derivados , Haloperidol/toxicidad , Animales , Antipsicóticos/toxicidad , Cafeína/administración & dosificación , Catalepsia/inducido químicamente , Catequina/administración & dosificación , Catequina/aislamiento & purificación , Catequina/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Peroxidación de Lípido/efectos de los fármacos , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Trastornos Parkinsonianos/tratamiento farmacológico , Trastornos Parkinsonianos/fisiopatología , Té/químicaRESUMEN
Securinega virosa (Roxb ex. Willd) Baill. is a plant which is commonly used in African traditional medicine in management of mental illness. Previous study showed that the crude methanolic root bark extract of the plant possesses antipsychotic activity. In this study, the antipsychotic potential of the residual aqueous fraction of the plant was evaluated using two experimental models, apomorphine induced stereotypic climbing behaviour and swim induced grooming, all in mice. The effect of the fraction on haloperidol-induced catalepsy was also evaluated. The fraction significantly reduced the mean climbing score at the highest dose tested (500 mg/kg). In the swim-induced grooming test, the fraction significantly and dose-dependently (125-500 mg/kg) decreased the mean number and mean duration of swim-induced grooming activity in mice. Similarly, the standard haloperidol (1 mg/kg) significantly (p < 0.001) decreased the mean grooming episodes and duration. However, the fraction did not significantly potentiate haloperidol-induced catalepsy. These results suggest that the residual aqueous fraction of methanol root bark extract of Securinega virosa contains biological active principle with antipsychotic potential.
Asunto(s)
Antipsicóticos/uso terapéutico , Euphorbiaceae , Fitoterapia , Corteza de la Planta/química , Extractos Vegetales/uso terapéutico , Raíces de Plantas/química , Animales , Antipsicóticos/aislamiento & purificación , Apomorfina/toxicidad , Catalepsia/inducido químicamente , Catalepsia/tratamiento farmacológico , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Femenino , Aseo Animal/efectos de los fármacos , Haloperidol/farmacología , Haloperidol/toxicidad , Masculino , Medicinas Tradicionales Africanas , Metanol , Ratones , Extractos Vegetales/aislamiento & purificación , Solventes , Conducta Estereotipada/efectos de los fármacos , Natación , AguaRESUMEN
Free radical-mediated abnormalities may contribute toward the pathogenesis of tardive dyskinesia (TD). Many studies have reported the protective antioxidant and free radical-scavenging activities of extract of Ginkgo biloba (EGb761) against free radical-induced cell damage and dysfunction. This study aimed to compare the efficacy of EGb761 with that of vitamin E for the prevention and treatment of TD in a rat model. We carried out two studies. First, rats were injected with haloperidol (2 mg/kg intraperitoneally) daily for 5 weeks. EGb761 (50 mg/kg/day) or vitamin E (20 mg/kg/day) were then administered for another 5 weeks, and their effects on vacuous chewing movements (VCMs) were compared. Second, we compared 10 weeks of haloperidol alone with 10 weeks of haloperidol plus EGb761 or vitamin E. The administration of haloperidol led to a progressive increase in VCMs, which peaked at week 5. In study one, EGb761 and vitamin E, administered by an oral gavage for 5 weeks during withdrawal from chronic haloperidol treatment, decreased VCMs significantly, showing 83.8 and 91.0% reduction, respectively, compared with the haloperidol-alone group. In study two, the concomitant administration of EGb761 and vitamin E led to significantly fewer VCMs, by 64.4 and 73.9%, respectively, compared with the haloperidol-alone group. There was no significant difference in either study between EGb761 and vitamin E treatment. EGb761 shows promise for the prevention and treatment of TD in a rat model with a magnitude that was similar to that of vitamin E.
Asunto(s)
Discinesia Inducida por Medicamentos/prevención & control , Masticación/efectos de los fármacos , Extractos Vegetales/farmacología , Vitamina E/farmacología , Animales , Antioxidantes/aislamiento & purificación , Antioxidantes/farmacología , Antipsicóticos/toxicidad , Modelos Animales de Enfermedad , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Depuradores de Radicales Libres/farmacología , Ginkgo biloba , Haloperidol/toxicidad , Masculino , Ratas , Ratas Sprague-DawleyRESUMEN
Effects of yokukansan (YKS) on vacuous chewing movement (VCM), which is an index for tardive dyskinesia, were investigated in haloperidol decanoate-treated rats. Haloperidol decanoate was injected to a thigh muscle once every four weeks for 18 weeks. The rats which exhibited VCM eight times or more in 3min were selected on the 12th week, and examined. A significant increase in VCM on the 12th week continued until the 18th week. Oral administration of YKS (0.1 and 0.5g/kg) once a day for three weeks (21 days) from the 12th week to 15th week ameliorated the haloperidol decanoate-induced increase in VCM in a dose-dependent manner. The significant ameliorative effect observed in 0.5g/kg YKS-treated rats was abolished by stopping administration for three weeks from the 15th week to the 18th week. The extracellular glutamate concentration and glutamate transporter mRNA expression in the striatum were evaluated by microdialysis and real-time reverse-transcription polymerase chain reaction assays at the 15th week. The striatal glutamate level increased in haloperidol-treated rats, and the increase was inhibited by treatment with YKS. The striatal GLT-1 mRNA level showed a tendency to decrease in the haloperidol-treated rats. The GLT-1 mRNA level after treatment with YKS (0.5g/kg) was greater than the control level. These results suggest the effect of YKS may be involved in the extracellular glutamate level and GLT-1 mRNA expression in the striatum.
Asunto(s)
Modelos Animales de Enfermedad , Medicamentos Herbarios Chinos/uso terapéutico , Discinesia Inducida por Medicamentos/metabolismo , Transportador 2 de Aminoácidos Excitadores/biosíntesis , Ácido Glutámico/biosíntesis , Haloperidol/toxicidad , Animales , Células CHO , Cricetinae , Cricetulus , Medicamentos Herbarios Chinos/farmacología , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Humanos , Masculino , Masticación , Movimiento/efectos de los fármacos , Movimiento/fisiología , Ratas , Ratas Wistar , Resultado del TratamientoRESUMEN
The brain is protected by a physiological blood-brain barrier (BBB) against toxins and some metabolites circulating in the blood. At the same time, the BBB limits penetration into the brain of many neuroactive drugs. Efficient ways to increase BBB permeability for delivery of drugs of different chemical nature into the brain are unknown. This work deals with delivery into the brain of 10(-2) M dopamine, a substance that does not penetrate the BBB under normal circumstances. It was studied in two independent experiments: (i) penetration of (3)H-labeled dopamine from its mixture with 10(-5) M H2O2 into hypothalamus and striatum structures of intact rat brain, and (ii) effect of unlabeled dopamine from a mixture with H(2)O(2) on the rat motor activity in a haloperidol catalepsy model. It was shown that (i) at the third minute after nasal application of the dopamine + H(2)O(2) mixture, the dopamine level increases 45-fold in the hypothalamus and almost 30-fold in the striatum and (ii) motility of animals in the catalepsy haloperidol model is recovered 90 sec after intranasal introduction of dopamine. No such effects were observed after replacement of H(2)O(2) by 0.9% NaCl solution. Thus, it was shown on the example of dopamine that its introduction into the nasal cavity simultaneously with H(2)O(2) provides for rapid delivery of the drug into the brain. These results expand our knowledge concerning the biological role of exoROS in modulating BBB permeability and may contribute to the development of a new therapeutic strategy for neurological diseases.
Asunto(s)
Barrera Hematoencefálica/metabolismo , Ácido 3,4-Dihidroxifenilacético/análisis , Administración Intranasal , Animales , Catalepsia/inducido químicamente , Catalepsia/metabolismo , Catalepsia/patología , Cromatografía Líquida de Alta Presión , Cuerpo Estriado/metabolismo , Modelos Animales de Enfermedad , Dopamina/análisis , Dopamina/farmacología , Dopaminérgicos/análisis , Dopaminérgicos/farmacología , Haloperidol/toxicidad , Peróxido de Hidrógeno/farmacología , Hipotálamo/metabolismo , Marcaje Isotópico , Masculino , Actividad Motora/efectos de los fármacos , Ratas , Ratas Wistar , Especies Reactivas de Oxígeno/metabolismo , Tritio/químicaRESUMEN
Modelling neurological diseases has proven extraordinarily difficult due to the phenotypic complexity of each disorder. The zebrafish has become a useful model system with which to study abnormal neurological and behavioural activity and holds promise as a model of human disease. While most of the disease modelling using zebrafish has made use of adults, larvae hold tremendous promise for the high-throughput screening of potential therapeutics. The further development of larval disease models will strengthen their ability to contribute to the drug screening process. Here we have used zebrafish larvae to model the symptoms of bipolar disorder by treating larvae with sub-convulsive concentrations of the GABA antagonist pentylenetetrazol (PTZ). A number of therapeutics that act on different targets, in addition to those that have been used to treat bipolar disorder, were tested against this model to assess its predictive value. Carbamazepine, valproic acid, baclofen and honokiol, were found to oppose various aspects of the PTZ-induced changes in activity. Lidocaine and haloperidol exacerbated the PTZ-induced activity changes and sulpiride had no effect. By comparing the degree of phenotypic rescue with the mechanism of action of each therapeutic we have shown that the low-concentration PTZ model can produce a number of intermediate phenotypes that model symptoms of bipolar disorder, may be useful in modelling other disease states, and will help predict the efficacy of novel therapeutics.
Asunto(s)
Ansiolíticos/uso terapéutico , Trastorno Bipolar/tratamiento farmacológico , Evaluación Preclínica de Medicamentos/métodos , Análisis de Varianza , Animales , Antipsicóticos/efectos adversos , Trastorno Bipolar/inducido químicamente , Adaptación a la Oscuridad/efectos de los fármacos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Antagonistas del GABA/toxicidad , Haloperidol/toxicidad , Larva , Lidocaína/toxicidad , Pentilenotetrazol/toxicidad , Convulsiones/inducido químicamente , Convulsiones/tratamiento farmacológico , Convulsiones/fisiopatología , Grabación en Video , Pez CebraRESUMEN
In the traditional Sardinian system of medicine, Rubia peregrina L. (Rubiaceae) is reported as an aphrodisiac herb. Since the aphrodisiacs may also have antioxidant and dopaminergic activities, the aim of this study was to study the effect of ethanolic extract of aerial parts of R. peregrina for the scavenging of free DPPH radicals and the inhibition of haloperidol-induced catalepsy in mice and reserpine-induced orofacial dyskinesia in rats. The extract exhibited significant antioxidant activity in a free radical DPPH assay with IC(50) = 55.6 µg mL(-1), which was very close to IC(50) of ascorbic acid. The extract of R. peregrina (100 and 200 mg kg(-1) intraperitoneally, i.p.) significantly inhibited haloperidol (1 mg kg(-1) i.p.) - induced catalepsy in mice (p < 0.01). In rats, the extract (200 mg kg(-1) i.p.) significantly (p < 0.01) inhibited the orofacial dyskinesia induced by intraperitoneal administration of reserpine (1 mg kg(-1) on days 1, 3 and 5). This study demonstrates that R. peregrina has antioxidant activity and improves the dopaminergic function. Results therefore justify the development of further experiments to investigate the psychopharmacological profile of R. peregrina.
Asunto(s)
Catalepsia/inducido químicamente , Catalepsia/tratamiento farmacológico , Etanol/química , Haloperidol/toxicidad , Trastornos del Movimiento/tratamiento farmacológico , Trastornos del Movimiento/etiología , Extractos Vegetales/uso terapéutico , Reserpina/toxicidad , Rubia/química , Animales , Masculino , Extractos Vegetales/química , RatasRESUMEN
Agonists for neurotensin (NT)-1 receptors have produced antipsychotic-like effects in many animals, including reversal of prepulse inhibition deficits and psychostimulant-induced increases in spontaneous activity. The present study sought to provide a basic assessment of the putative antipsychotic effects of PD149163 in rats using a two way conditioned avoidance response task, which is highly validated for screening antipsychotic drugs, and an inclined grid assessment, which is used to assess extrapyramidal side effect liability. PD149163 (0.0625-8.0 mg/kg) significantly suppressed conditioned avoidance responding (CAR) following administration of a 1.0 or 8.0 mg/kg dose. PD149163 failed to significantly increase catalepsy scores. The typical antipsychotic drug haloperidol (0.01-1.0 mg/kg) significantly suppressed CAR at a 0.1, 0.3, and 1.0 mg/kg dose, and a significant increase in catalepsy scores was found at the 1.0 mg/kg dose. The atypical antipsychotic drug clozapine (2.5-10.0 mg/kg) also produced a significant inhibition of CAR, which occurred following administration of a 10.0 mg/kg dose. Clozapine failed to significantly increase catalepsy scores. Finally, D-amphetamine (1.0 mg/kg), serving as a negative control, failed to suppress CAR or increase catalepsy scores. These data further suggest that PD149163 may have atypical antipsychotic-like properties.
Asunto(s)
Antipsicóticos/farmacología , Catalepsia/inducido químicamente , Neurotensina/análogos & derivados , Receptores de Neurotensina/agonistas , Animales , Antipsicóticos/toxicidad , Reacción de Prevención/efectos de los fármacos , Estimulantes del Sistema Nervioso Central/farmacología , Estimulantes del Sistema Nervioso Central/toxicidad , Clozapina/farmacología , Clozapina/toxicidad , Condicionamiento Clásico/efectos de los fármacos , Dextroanfetamina/farmacología , Dextroanfetamina/toxicidad , Evaluación Preclínica de Medicamentos , Haloperidol/efectos adversos , Haloperidol/farmacología , Haloperidol/toxicidad , Masculino , Neurotensina/farmacología , Neurotensina/toxicidad , Ratas , Ratas Sprague-DawleyRESUMEN
Neuroleptic-induced tardive dyskinesia (TD) is a motor disorder of the orofacial region resulting from chronic neuroleptic treatment. The agents improving dopaminergic transmission improve TD. Mucuna pruriens seed contains levodopa and amino acids. The effect of methanolic extract of M. pruriens seeds (MEMP) was studied on haloperidol-induced TD, alongside the changes in lipid peroxidation, reduced glutathione, superoxide dismutase (SOD) and catalase levels. The effect of MEMP was also evaluated in terms of the generation of hydroxyl and 1,1-diphenyl,2-picrylhydrazyl (DPPH) radical. MEMP (100 and 200 mg kg⻹) inhibited haloperidol-induced vacuous chewing movements, orofacial bursts and biochemical changes. MEMP also inhibited hydroxyl radical generation and DPPH. The results of the present study suggest that MEMP by virtue of its free radical scavenging activity prevents neuroleptic-induced TD.
Asunto(s)
Acatisia Inducida por Medicamentos/tratamiento farmacológico , Haloperidol/toxicidad , Mucuna/química , Extractos Vegetales/uso terapéutico , Animales , Antioxidantes/uso terapéutico , Radicales Libres/metabolismo , Masculino , Extractos Vegetales/química , Ratas , Ratas Wistar , Vitamina E/uso terapéuticoRESUMEN
Long-term treatment with haloperidol, a typical neuroleptic, induces neurodegeneration caused by excitotoxicity and oxidative stress, which play an important role in the development of orofacial dyskinesia. In the present investigation, an attempt has been made to examine the effect of a concomitant treatment of methanol extract of Morus alba Linn. (Moraceae) leaves (100-300 mg/kg, i.p.) and haloperidol (1 mg/kg, i.p.) on an animal model of tardive dyskinesia. Rats were treated for 21 days with haloperidol and Morus alba extract; vacuous chewing movements and tongue protrusions were counted. The extract attenuated the increase in vacuous chewing movements and tongue protrusions induced by haloperidol, which were quantified on day 22. The extract showed a marked effect on behavioral parameters altered by haloperidol treatment. Similar treatment with extract attenuated haloperidol-induced lipid peroxidation and nitrite and normalized superoxide dismutase, catalase, and protein in comparison to the control group. The results suggest a protective effect of Morus alba extract against haloperidol-induced orofacial dyskinesia and oxidative stress.
Asunto(s)
Discinesia Inducida por Medicamentos/prevención & control , Haloperidol/toxicidad , Morus , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/uso terapéutico , Hojas de la Planta , Animales , Discinesia Inducida por Medicamentos/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Peroxidación de Lípido/fisiología , Masculino , Trastornos del Movimiento/metabolismo , Trastornos del Movimiento/prevención & control , Estrés Oxidativo/fisiología , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología , Ratas , Ratas WistarRESUMEN
The effects of fish oil supplementation on motor disorders, memory dysfunction, and lipid peroxidation (LP) induced by typical neuroleptics were studied. Wistar rats received a suspension prepared with fish oil containing omega-3 fatty acids, water, and Tween 80 (1%) in the place of drinking water (FO group) or vehicle (C group) for 8 weeks. After 4 weeks of treatment, half of the animals of both groups were treated with haloperidol (H and FO + H groups; experiment 1), fluphenazine (F and FO + F groups; experiment 2), or vehicle (C group), administered once a week (12 mg/kg/im) for 4 weeks, maintaining the treatment with FO. Extrapyramidal motor disorders by haloperidol and fluphenazine were observed by an increase in vacuous chewing movements and catalepsy (P < 0.05). These effects were reduced by FO treatment (P < 0.05). Both neuroleptics displayed impairment in memory retention observed by latency time to find the original location of platform in water-maze task, after 4 days of training performed in the last treatment week. This effect was reduced by FO (P < 0.05) to both haloperidol and fluphenazine treatments. Haloperidol increased the LP in plasma and hippocampus, and these effects were decreased by FO treatment (P < 0.05). Fluphenazine increased the LP in plasma and substantia nigra, which were completely decreased by FO treatment (P < 0.05). The FO decreased the motor disorders, memory dysfunction, and oxidative damage typical neuroleptic-induced. Our results indicate that FO exhibits a neuroprotector role useful on diseases related to oxidative damages, and may be considered in the prevention of motor and memory side effects induced by the antipsychotic treatment.
Asunto(s)
Catalepsia/tratamiento farmacológico , Ácidos Grasos Omega-3/uso terapéutico , Trastornos de la Memoria/tratamiento farmacológico , Trastornos del Movimiento/tratamiento farmacológico , Sustancias Reactivas al Ácido Tiobarbitúrico/metabolismo , Análisis de Varianza , Animales , Antipsicóticos/toxicidad , Conducta Animal/efectos de los fármacos , Catalepsia/inducido químicamente , Modelos Animales de Enfermedad , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Discinesia Inducida por Medicamentos/etiología , Ácidos Grasos Omega-3/farmacología , Haloperidol/análogos & derivados , Haloperidol/toxicidad , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Trastornos de la Memoria/inducido químicamente , Trastornos del Movimiento/etiología , Ratas , Ratas Wistar , Factores de TiempoRESUMEN
Haloperidol (HAL) is a widely used neuroleptic drug for the treatment of acute and chronic psychosis. Tardive dyskinesia (TD) is a complex hyperkinetic syndrome consisting of choreiform and athetoid movements, which persists for months or years after withdrawal. Increased levels of thiobarbituric acid reactive products are found in the cerebrospinal fluid and plasma of patients treated with neuroleptics, especially those with movement disorders. Alpha lipoic acid (ALA), a natural metabolic antioxidant, is effective in both prevention and treatment of numerous types of neurological disorders. It is proposed to study the effect of ALA on TD induced by HAL and to correlate it with oxidative stress by studying total antioxidant status and lipid peroxidation (LP). HAL (1 mg/kg/i.p.) was used to induce vacuous chewing movements in rats. ALA was suspended in 0.2% carboxy methyl cellulose at a dose of 25, 50 and 100 mg/kg and was administered orally by oral gavage 1 h before HAL on 21st day of treatment. ALA supplementation significantly decreased HAL-induced TD at a dose of 100 mg/kg and catalepsy dose dependently. ALA improved TD and catalepsy by decreasing HAL-induced LP. ALA and its metabolite dihydro lipoic acid protect against HAL-induced TD and catalepsy by scavenging reactive oxygen species and reactive nitrogen species.
Asunto(s)
Antioxidantes/farmacología , Encéfalo/efectos de los fármacos , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Haloperidol/antagonistas & inhibidores , Estrés Oxidativo/efectos de los fármacos , Ácido Tióctico/farmacología , Animales , Antipsicóticos/toxicidad , Encéfalo/metabolismo , Encéfalo/fisiopatología , Catalepsia/inducido químicamente , Catalepsia/tratamiento farmacológico , Catalepsia/metabolismo , Relación Dosis-Respuesta a Droga , Discinesia Inducida por Medicamentos/metabolismo , Discinesia Inducida por Medicamentos/fisiopatología , Radicales Libres/antagonistas & inhibidores , Radicales Libres/metabolismo , Haloperidol/toxicidad , Peroxidación de Lípido/efectos de los fármacos , Peroxidación de Lípido/fisiología , Masculino , Estrés Oxidativo/fisiología , Ratas , Ratas Wistar , Especies de Nitrógeno Reactivo/antagonistas & inhibidores , Especies de Nitrógeno Reactivo/metabolismo , Especies Reactivas de Oxígeno/antagonistas & inhibidores , Especies Reactivas de Oxígeno/metabolismo , Ácido Tióctico/análogos & derivados , Ácido Tióctico/metabolismo , Resultado del TratamientoRESUMEN
Tardive dyskinesia (TD) is a motor disorder of the orofacial region resulting from chronic neuroleptic treatment. A high incidence and irreversibility of this hyperkinetic disorder has been considered a major clinical issue in the treatment of schizophrenia. The molecular mechanism related to the pathophysiology of tardive dyskinesia is not completely known. Various animal studies have demonstrated an enhanced oxidative stress and increased glutamatergic transmission as well as inhibition in the glutamate uptake after the chronic administration of haloperidol. The present study investigated the effect of curcumin, an antioxidant, in haloperidol-induced tardive dyskinesia by using different behavioural (orofacial dyskinetic movements, stereotypy, locomotor activity, % retention), biochemical (lipid peroxidation, reduced glutathione levels, antioxidant enzyme levels (SOD and catalase) and neurochemical (neurotransmitter levels) parameters. Chronic administration of haloperidol (1 mg/kg i.p. for 21 days) significantly increased vacuous chewing movements (VCM's), tongue protrusions, facial jerking in rats which was dose-dependently inhibited by curcumin. Chronic administration of haloperidol also resulted in increased dopamine receptor sensitivity as evident by increased locomotor activity and stereotypy and also decreased % retention time on elevated plus maze paradigm. Pretreatment with curcumin reversed these behavioral changes. Besides, haloperidol also induced oxidative damage in all major regions of brain which was attenuated by curcumin, especially in the subcortical region containing striatum. On chronic administration of haloperidol, there was a decrease in turnover of dopamine, serotonin and norepinephrine in both cortical and subcortical regions which was again dose-dependently reversed by treatment with curcumin. The findings of the present study suggested for the involvement of free radicals in the development of neuroleptic-induced tardive dyskinesia and point to curcumin as a possible therapeutic option to treat this hyperkinetic movement disorder.
Asunto(s)
Antidiscinéticos , Antipsicóticos/antagonistas & inhibidores , Antipsicóticos/toxicidad , Conducta Animal/efectos de los fármacos , Química Encefálica/efectos de los fármacos , Curcuma/química , Curcumina/uso terapéutico , Discinesia Inducida por Medicamentos/prevención & control , Haloperidol/antagonistas & inhibidores , Haloperidol/toxicidad , Animales , Ansiolíticos/farmacología , Peso Corporal/efectos de los fármacos , Catalasa/metabolismo , Discinesia Inducida por Medicamentos/psicología , Glutatión/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Masculino , Actividad Motora/efectos de los fármacos , Proteínas del Tejido Nervioso/metabolismo , Neurotransmisores/metabolismo , Ratas , Ratas Wistar , Conducta Estereotipada/efectos de los fármacos , Compuestos de Sulfhidrilo/metabolismo , Superóxido Dismutasa/metabolismoRESUMEN
Chronic treatment with classical neuroleptics in humans can produce a serious side effect, known as tardive dyskinesia (TD). Here, we examined the effects of V. officinalis, a medicinal herb widely used as calming and sleep-promoting, in an animal model of orofacial dyskinesia (OD) induced by long-term treatment with haloperidol. Adult male rats were treated during 12 weeks with haloperidol decanoate (38 mg/kg, i.m., each 28 days) and with V. officinalis (in the drinking water). Vacuous chewing movements (VCMs), locomotor activity and plus maze performance were evaluated. Haloperidol treatment produced VCM in 40% of the treated rats and the concomitant treatment with V. officinalis did not alter either prevalence or intensity of VCMs. The treatment with V. officinalis increased the percentage of the time spent on open arm and the number of entries into open arm in the plus maze test. Furthermore, the treatment with haloperidol and/or V. officinalis decreased the locomotor activity in the open field test. We did not find any difference among the groups when oxidative stress parameters were evaluated. Haloperidol treatment significantly decreased [(3)H]-dopamine uptake in striatal slices and V. officinalis was not able to prevent this effect. Taken together, our data suggest a mechanism involving the reduction of dopamine transport in the maintenance of chronic VCMs in rats. Furthermore, chronic treatment with V. officinalis seems not produce any oxidative damage to central nervous system (CNS), but it also seems to be devoid of action to prevent VCM, at least in the dose used in this study.
Asunto(s)
Antipsicóticos/toxicidad , Antagonistas de Dopamina/toxicidad , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/fisiología , Haloperidol/toxicidad , Trastornos del Movimiento/tratamiento farmacológico , Valeriana/química , Animales , Ansiedad/psicología , Conducta Animal/efectos de los fármacos , Química Encefálica/efectos de los fármacos , Dopamina/metabolismo , Masculino , Actividad Motora/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/uso terapéutico , Ratas , Ratas WistarRESUMEN
The therapeutic management of methamphetamine (METH)-induced psychoses often involves treatment with the typical antipsychotic drug and dopamine D2 receptor antagonist haloperidol. We report here that subchronic haloperidol administration after a high-dose regimen of METH produces a heretofore unrecognized toxicity to GABAergic cells, as reflected by GAD67 mRNA expression histochemistry, in the rat substantia nigra pars reticulata (SNr) through an acute and persistent augmentation of glutamate release, NMDA receptor activation, and DNA fragmentation. The dopaminergic cells in the substantia nigra pars compacta were unaffected by METH or haloperidol alone or the combination of METH and haloperidol. These findings suggest that the current therapeutic management of METH-induced psychoses with haloperidol may be contraindicated because of a resultant GABAergic cell death in the SNr, which may predispose some individuals to the development of hyperkinetic movement disorders and seizures.